Oncologica is a leading precision oncology services laboratory and contract research organisation based in the prestigious Chesterford Research Park, Cambridge, UK
Oncologica provides precision oncology testing to address the growing demand for molecular profiling of cancer patients for targeted therapies and functions as a Contract Research Organisation to support biomarker and drug development programmes worldwide.
Our technology addresses this new era of precision medicine by exploiting state of the art molecular profiling enabling a patient’s tumour to be matched directly with the most appropriate molecular targeted therapy.
Oncologica was established in November 2014 to address the rapidly increasing demand for precision oncology. The potential to link specific genetic alterations to molecular targeted therapies is driving a new era of personalised medicine. Oncologica has risen to this challenge and taken full advantage of its in-depth expertise and knowledge in the molecular diagnostics field to establish the first laboratory in Europe to provide state of the art diagnostic platforms that enable the most comprehensive linkage of specific cancer genetic alterations to the most appropriate targeted therapy. Oncologica is at the forefront in Europe at providing a precision oncology service that can help ensure that patients can derive maximum benefit from the new generation of personalised drugs now reaching the clinic. Oncologica provides precision oncology testing to address the growing demand for molecular profiling of cancer patients for targeted therapies. Oncologica also functions as a Contract Research Organisation to support biomarker and drug development programmes worldwide. We capitalise on our extensive knowledge base in anatomical and molecular oncopathology to provide high quality and cost effective Contract Research Services to support theranostic programmes at all stages of the development pipeline, from discovery through preclinical development to clinical trials. In addition, Oncologica runs its own in-house R&D programmes focusing on the development of novel diagnostic and therapeutic intervention strategies targeting the cell cycle machinery. Our aim is to be a major driver of the new generation of molecular profiling for precision oncology to increase treatment efficacy and reduce healthcare costs.